mirtazapine has been researched along with Weight Loss in 9 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
Weight Loss: Decrease in existing BODY WEIGHT.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mirtazapine is classified as a weight gain drug in cats, and the purpose of this study was to evaluate its efficacy in cats experiencing unintended weight loss." | 9.30 | A double-blind, placebo-controlled, randomized study to evaluate the weight gain drug, mirtazapine transdermal ointment, in cats with unintended weight loss. ( Buhles, W; Hu, T; Labelle, D; Poole, M; Quimby, JM, 2019) |
| "In a randomized, placebo-controlled trial, mirtazapine significantly improved early satiation, quality of life, gastrointestinal-specific anxiety, nutrient tolerance, and weight loss in patients with FD." | 9.22 | Efficacy of Mirtazapine in Patients With Functional Dyspepsia and Weight Loss. ( Arts, J; Boeckxstaens, G; Caenepeel, P; Carbone, F; Holvoet, L; Ly, HG; Tack, J; Van Oudenhove, L; Vanheel, H; Vanuytsel, T, 2016) |
| "Mirtazapine not only alleviates symptoms associated with dyspepsia and depression linked to FD in patients with weight loss but also significantly increases body weight (mainly the visceral fat in body fat)." | 9.22 | Beneficial effects of antidepressant mirtazapine in functional dyspepsia patients with weight loss. ( Jia, L; Jiang, SM; Liu, J; Shi, MM; Xu, MZ, 2016) |
| "Three patients with dementia and depression complicated by weight loss, insomnia, and anxiety were treated with mirtazapine at an outpatient memory loss clinic of a university hospital." | 7.71 | Mirtazapine for treatment of depression and comorbidities in Alzheimer disease. ( Brady, SR; Raji, MA, 2001) |
| "Mirtazapine is classified as a weight gain drug in cats, and the purpose of this study was to evaluate its efficacy in cats experiencing unintended weight loss." | 5.30 | A double-blind, placebo-controlled, randomized study to evaluate the weight gain drug, mirtazapine transdermal ointment, in cats with unintended weight loss. ( Buhles, W; Hu, T; Labelle, D; Poole, M; Quimby, JM, 2019) |
| "In a randomized, placebo-controlled trial, mirtazapine significantly improved early satiation, quality of life, gastrointestinal-specific anxiety, nutrient tolerance, and weight loss in patients with FD." | 5.22 | Efficacy of Mirtazapine in Patients With Functional Dyspepsia and Weight Loss. ( Arts, J; Boeckxstaens, G; Caenepeel, P; Carbone, F; Holvoet, L; Ly, HG; Tack, J; Van Oudenhove, L; Vanheel, H; Vanuytsel, T, 2016) |
| "Mirtazapine not only alleviates symptoms associated with dyspepsia and depression linked to FD in patients with weight loss but also significantly increases body weight (mainly the visceral fat in body fat)." | 5.22 | Beneficial effects of antidepressant mirtazapine in functional dyspepsia patients with weight loss. ( Jia, L; Jiang, SM; Liu, J; Shi, MM; Xu, MZ, 2016) |
| "Three patients with dementia and depression complicated by weight loss, insomnia, and anxiety were treated with mirtazapine at an outpatient memory loss clinic of a university hospital." | 3.71 | Mirtazapine for treatment of depression and comorbidities in Alzheimer disease. ( Brady, SR; Raji, MA, 2001) |
| " Adverse events were commonly seen in the oncology population." | 1.72 | Propensity score-matching analysis comparing safety outcomes of appetite-stimulating medications in oncology patients. ( Burger, A; Eladghm, N; Gamaleldin, A; Marie Gavioli, E; Vider, E, 2022) |
| "Changes in body weight can affect the overall health of an older patient and should not be considered a normal part of the aging process." | 1.40 | Potential role of mirtazapine in underweight older adults. ( Avena-Woods, C; Hilas, O, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Marie Gavioli, E | 1 |
| Burger, A | 1 |
| Gamaleldin, A | 1 |
| Eladghm, N | 1 |
| Vider, E | 1 |
| Poole, M | 1 |
| Quimby, JM | 1 |
| Hu, T | 1 |
| Labelle, D | 1 |
| Buhles, W | 1 |
| Hilas, O | 1 |
| Avena-Woods, C | 1 |
| Tanidir, C | 1 |
| Tanidir, IC | 1 |
| Tuzcu, V | 1 |
| Tack, J | 1 |
| Ly, HG | 1 |
| Carbone, F | 1 |
| Vanheel, H | 1 |
| Vanuytsel, T | 1 |
| Holvoet, L | 1 |
| Boeckxstaens, G | 1 |
| Caenepeel, P | 1 |
| Arts, J | 1 |
| Van Oudenhove, L | 1 |
| Jiang, SM | 1 |
| Jia, L | 1 |
| Liu, J | 1 |
| Shi, MM | 1 |
| Xu, MZ | 1 |
| Fox, CB | 1 |
| Treadway, AK | 1 |
| Blaszczyk, AT | 1 |
| Sleeper, RB | 1 |
| Goldberg, RJ | 1 |
| Raji, MA | 1 |
| Brady, SR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Mirtazapine Versus Placebo on Appetite, Nutritional Status and Quality of Life in Non-small Cell Lung cáncer Patients With Anorexia; Randomized Double-blind Clinical Trial.[NCT04748523] | 86 participants (Actual) | Interventional | 2018-08-29 | Completed | |||
| Phase 4 Study of Mirtazapine in Functional Dyspepsia Patients With Weight Loss[NCT01240096] | Phase 4 | 35 participants (Anticipated) | Interventional | 2006-09-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for mirtazapine and Weight Loss
| Article | Year |
|---|---|
Megestrol acetate and mirtazapine for the treatment of unplanned weight loss in the elderly.
Topics: Aged; Antidepressive Agents, Tricyclic; Appetite Stimulants; Cachexia; Case-Control Studies; Dose-Re | 2009 |
3 trials available for mirtazapine and Weight Loss
| Article | Year |
|---|---|
A double-blind, placebo-controlled, randomized study to evaluate the weight gain drug, mirtazapine transdermal ointment, in cats with unintended weight loss.
Topics: Administration, Cutaneous; Animals; Appetite Stimulants; Cat Diseases; Cats; Double-Blind Method; Fe | 2019 |
Efficacy of Mirtazapine in Patients With Functional Dyspepsia and Weight Loss.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Anxiety; Double-Blind Method; Dyspepsia; Female; Humans; | 2016 |
Beneficial effects of antidepressant mirtazapine in functional dyspepsia patients with weight loss.
Topics: Adiposity; Adult; Affect; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic | 2016 |
5 other studies available for mirtazapine and Weight Loss
| Article | Year |
|---|---|
Propensity score-matching analysis comparing safety outcomes of appetite-stimulating medications in oncology patients.
Topics: Adult; Aged; Anorexia; Appetite; Appetite Stimulants; Cachexia; Hallucinations; Humans; Long QT Synd | 2022 |
Potential role of mirtazapine in underweight older adults.
Topics: Aged; Antidepressive Agents, Tricyclic; Appetite; Body Weight; Humans; Mianserin; Mirtazapine; Quali | 2014 |
Treatment of depression in an adolescent with cardiomyopathy and arrhythmia.
Topics: Adolescent; Antidepressive Agents, Tricyclic; Anxiety; Cardiomyopathy, Hypertrophic; Depression; Ele | 2015 |
Weight change in depressed nursing home patients on mirtazapine.
Topics: Aged; Antidepressive Agents, Tricyclic; Depression; Female; Homes for the Aged; Humans; Male; Mianse | 2002 |
Mirtazapine for treatment of depression and comorbidities in Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents, Tricyclic; Comorbidity; Depressio | 2001 |